TY - JOUR
T1 - Quality-of-life and olfaction changes observed with short-term medical management of chronic rhinosinusitis
AU - Thomas, Andrew J.
AU - Mace, Jess C.
AU - Ramakrishnan, Vijay R.
AU - Alt, Jeremiah A.
AU - Mattos, Jose L.
AU - Schlosser, Rodney J.
AU - Soler, Zachary M.
AU - Smith, Timothy L.
N1 - Funding Information:
sources for the study: National Institute on Deafness and Other Communication Disorders (NIDCD) of the National Institutes of Health (R01 DC005805 to J.C.M., J.A.A., V.R.R., R.J.S., T.L.S., and Z.M.S. [co‒principal investigators: T.L.S. and Z.M.S.], public clinical trial registration [www.clinicaltrials.gov] identification number NCT02720653; NIDCD K23 DC04747 to V.R.R.). These funding organizations had no involvement in the design or conduct of this study, or in preparation, review, approval, or decision to submit this manuscript for publication.
Publisher Copyright:
© 2020 ARS-AAOA, LLC
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Background: Patients with chronic rhinosinusitis (CRS) commonly experience both reduced quality of life (QOL) and olfactory dysfunction (OD). Literature on the impacts of appropriate medical therapy (AMT) for CRS on QOL and OD is limited, and the focused design of these studies may limit their applicability to usual clinical practice. Methods: Adults with symptomatic CRS were prospectively enrolled (November 2016 to October 2018) into an observational, multi-institutional study. Individualized AMT was initiated using standard practice according to evidence-based guidelines. Endoscopy examination (Lund-Kennedy), olfactory function (Sniffin’ Sticks) testing, and QOL survey responses (22-item Sino-Nasal Outcome Test [SNOT-22], Questionnaire of Olfactory Disorders―Negative Statements [QOD-NS]) were obtained at enrollment and follow-up. Results: Baseline measures demonstrated heterogeneity of QOL and OD. After an average of 7.8 weeks, within-subject median SNOT-22 total improved by 39.5% (n = 39, p < 0.001) relative to baseline, including 50% (p = 0.014) improvement for item #21, “Sense of smell/taste.” QOD-NS improvement was also statistically significant (p = 0.044). Sniffin’ Sticks score relative improvement of 10.9% (n = 33, p = 0.109) was not statistically significant and lacked correlation with SNOT-22 total scores (R = −0.247, p = 0.165) or QOD-NS total scores (R = −0.016, p = 0.930), but correlated moderately with endoscopy score (R = −0.436, p = 0.018). Conclusions: Participants with varied impacts of CRS, treated with individualized short-term AMT, demonstrated significant improvements in CRS- and olfactory-specific QOL measures, without corresponding improvement in clinically measured olfactory function. Olfactory function changes moderately correlated with endoscopy score changes, but lacked an association with QOL measurements.
AB - Background: Patients with chronic rhinosinusitis (CRS) commonly experience both reduced quality of life (QOL) and olfactory dysfunction (OD). Literature on the impacts of appropriate medical therapy (AMT) for CRS on QOL and OD is limited, and the focused design of these studies may limit their applicability to usual clinical practice. Methods: Adults with symptomatic CRS were prospectively enrolled (November 2016 to October 2018) into an observational, multi-institutional study. Individualized AMT was initiated using standard practice according to evidence-based guidelines. Endoscopy examination (Lund-Kennedy), olfactory function (Sniffin’ Sticks) testing, and QOL survey responses (22-item Sino-Nasal Outcome Test [SNOT-22], Questionnaire of Olfactory Disorders―Negative Statements [QOD-NS]) were obtained at enrollment and follow-up. Results: Baseline measures demonstrated heterogeneity of QOL and OD. After an average of 7.8 weeks, within-subject median SNOT-22 total improved by 39.5% (n = 39, p < 0.001) relative to baseline, including 50% (p = 0.014) improvement for item #21, “Sense of smell/taste.” QOD-NS improvement was also statistically significant (p = 0.044). Sniffin’ Sticks score relative improvement of 10.9% (n = 33, p = 0.109) was not statistically significant and lacked correlation with SNOT-22 total scores (R = −0.247, p = 0.165) or QOD-NS total scores (R = −0.016, p = 0.930), but correlated moderately with endoscopy score (R = −0.436, p = 0.018). Conclusions: Participants with varied impacts of CRS, treated with individualized short-term AMT, demonstrated significant improvements in CRS- and olfactory-specific QOL measures, without corresponding improvement in clinically measured olfactory function. Olfactory function changes moderately correlated with endoscopy score changes, but lacked an association with QOL measurements.
KW - chronic disease
KW - outcome assessment (health care)
KW - quality of life
KW - sinusitis
KW - smell
KW - therapeutics
UR - http://www.scopus.com/inward/record.url?scp=85078928837&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078928837&partnerID=8YFLogxK
U2 - 10.1002/alr.22532
DO - 10.1002/alr.22532
M3 - Article
C2 - 32017433
AN - SCOPUS:85078928837
SN - 2042-6976
VL - 10
SP - 656
EP - 664
JO - International Forum of Allergy and Rhinology
JF - International Forum of Allergy and Rhinology
IS - 5
ER -